Potenza Therapeutics   Report issue

For profit Phase 1
Founded: Cambridge MA United States (2014)
Status: Acquired by Astellas (2018) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
2017
NCT03260322
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Potenza Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (4)

asp1948 (1 trial)

asp8374 (1 trial)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 4